Appears on
Articles5
Time to emphasise the economics in health economics
Victoria Jordan, ABPI Value and Access Policy Director, discusses the Health Economics of the UK-US Economic Prosperity Deal and the commitment to increase NICE's baseline threshold use, the first change since its introduction in the early 2000s.
Is investing in medicines harming the health of the UK population?
A recent study published in the Lancet has disputed the existing decision-making threshold used by NICE. The authors argue that allowing NHS patients access to new NICE-recommended medicines has, counterintuitively, harmed wider population health by displacing other more cost-effective areas of spending. In this blog, Victoria Jordan explains why the ABPI di
What does the latest data tell us about NHS patients' access to medicines?
Understanding how well the system performs in meeting the NHS’s ambition for patients to have rapid access to effective new medicines is not easy. There are several sources of data, and like any reporting of metrics, it isn’t always immediately obvious what the data includes/excludes.
Updates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicines
NHS England (NHSE) has published an update to the commercial framework for new medicines. In this article, Victoria Jordan, ABPI’s Director of Value and Access Policy, reflects on what has been achieved and what must be prioritised as phase two of the consultation approaches.
Why the government must urgently raise the NICE cost-effectiveness threshold
In this piece, Victoria Jordan, ABPI's Director, Value and Access Policy, explains why the government must increase NICE’s baseline threshold to ensure that NHS patients benefit from timely access to the latest treatments.